Pulse Biosciences (NASDAQ:PLSE) Sets New 1-Year High – Still a Buy?

Pulse Biosciences, Inc (NASDAQ:PLSE) shares reached a new 52-week high on Tuesday . The stock traded as high as $50.90 and last traded at $49.3210, with a volume of 21355 shares changing hands. The stock had previously closed at $49.13.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on PLSE. Mizuho set a $45.00 price objective on shares of Pulse Biosciences in a research report on Monday, August 10th. Wall Street Zen lowered Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 8th. Oppenheimer reiterated an “outperform” rating on shares of Pulse Biosciences in a report on Tuesday, July 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research note on Friday, July 17th. Finally, Canaccord Genuity Group boosted their price objective on Pulse Biosciences from $32.00 to $43.00 and gave the company a “buy” rating in a report on Monday, August 10th. Four research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $45.25.

Pulse Biosciences Trading Up 0.3%

The stock has a market capitalization of $3.41 billion, a PE ratio of -41.58 and a beta of 1.61. The stock’s fifty day simple moving average is $33.55 and its 200-day simple moving average is $26.18.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.36) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.07). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.53 million. As a group, analysts anticipate that Pulse Biosciences, Inc will post -1.29 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Pulse Biosciences

Several hedge funds have recently modified their holdings of PLSE. BlackRock Inc. bought a new position in shares of Pulse Biosciences in the second quarter valued at approximately $40,672,000. Bank of America Corp DE bought a new stake in Pulse Biosciences during the second quarter worth $40,115,000. California State Teachers Retirement System boosted its position in Pulse Biosciences by 2,600.0% in the second quarter. California State Teachers Retirement System now owns 567,883 shares of the company’s stock worth $15,747,000 after purchasing an additional 546,850 shares during the last quarter. State Street Corp boosted its position in Pulse Biosciences by 6.0% in the fourth quarter. State Street Corp now owns 447,067 shares of the company’s stock worth $6,138,000 after purchasing an additional 25,187 shares during the last quarter. Finally, Brooklyn Investment Group boosted its position in Pulse Biosciences by 330.7% in the fourth quarter. Brooklyn Investment Group now owns 130,340 shares of the company’s stock worth $1,844,000 after purchasing an additional 100,081 shares during the last quarter. Institutional investors own 76.95% of the company’s stock.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc is a clinical-stage bioelectric medicine company that develops and commercializes medical devices based on its proprietary Tissue NanoPoration (TNP) platform. The company’s core technology, NanoPulse Stimulation (NPS), delivers ultrashort, high-voltage electric pulses to targeted tissue, triggering cellular responses without the thermal damage associated with traditional energy-based devices. Pulse Biosciences focuses on applications in dermatology and aesthetic medicine, where controlled ablation of unwanted lesions is critical.

The company’s flagship product, the CellFX® System, is designed to treat a range of benign and malignant skin lesions, including seborrheic keratosis, non-melanoma skin cancers, and various epidermal and dermal lesions.